Cognition Therapeutics completes positive FDA meeting on zervimesine registrational program for DLB psychosis.

Cognition Therapeutics held a productive meeting with the FDA on May 20, 2026 to discuss Phase 2 results for zervimesine (CT1812) in dementia with Lewy bodies with psychosis and obtain guidance on advancing into late-stage trials. The positive discussion on the path forward is encouraging for the company's lead candidate and could accelerate its development toward potential commercialization in a significant neurodegenerative disease indication.